ClinicalTrials.gg
CompletedNCT04038957Updated Dec 27, 2024Results posted

A Clinical Study to Investigate the Effect of an Investigational Drug as an Added Medication to an Antipsychotic, in Adults With Schizophrenia, as Measured Positron Emission Tomography (PET) Imaging

A Phase 1 interventional study of SEP-363856 in Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2024-12-27.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 23 studies testing SEP-363856 in Schizophrenia — 1 open to participants now, 2 under way, 2 of them phase 3. SEP-363856 · Schizophrenia.

Enrollment
19th of 23
22 · median 83
Started
2019
with 4 others
Phase 1
11 of 23
none open now
Registered
6th of 23
by date
Lead sponsor
18 of 23
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 23 studies testing SEP-363856 in Schizophrenia, this one is the 19th largest by enrollment, is one of 5 that started in 2019, is one of 11 in phase 1, and was the 6th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

1 of the 23 studies testing SEP-363856 in Schizophrenia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About SEP-363856

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing SEP-363856 in Schizophrenia, or all of them as a file.
02

Study summary

A clinical study to investigate the effect of an investigational drug as an added medication to an antipsychotic, in adults with schizophrenia, as measured positron emission tomography (PET) imaging . This study is accepting male and female participants between 18 years old -45 years old who have been diagnosed with schizophrenia. This study will be conducted in 2 locations in the UK. The study will last approximately 14 months.

Read the detailed description

This is a single-site, open-label, flexibly-dosed study evaluating the effect on brain dopamine synthesis capacity as measured by 18F-DOPA PET imaging of adjunctive open-label administration of SEP-363856 (50 to 75 mg/day) over 2 weeks in adults with schizophrenia. The study will consist of 3 periods: Screening (up to 28 days), Treatment (2 weeks), and a Follow-up visit

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • schizophrenia
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-1. Subject must give written and privacy authorization prior to participation in the study.

  1. Subject must be willing and able to comply with the study procedures and visit schedule, including required minimum week in-clinic treatment period, and must be able to understand and follow verbal and written instructions
  • Male or female subject between 18 to 45 years of age (inclusive) at the time of consent
  • Subject meets (DSM-5) criteria for a primary diagnosis of schizophrenia as established by clinical interview (using the DSM-5 as a reference and confirmed using the Structured Clinical Interview for DSM-V Clinical Trials Version [SCID-CT]). The duration of the subject's illness whether treated or untreated must be ≥ 6 months.
  • Subject must be on a stable dose of a single antipsychotic medication, dosed within the labeled dose-range, for a minimum of 3 weeks prior to the PET scan at the screening visit. Patients taking clozapine are not eligible to participate
  • Subject must have a Clinical Global Impression-Severity (CGI-S) score ≥ 3 (mild or greater)
  • Subject must have a Positive and Negative Syndrome Scale (PANSS) total score ≥ 70.
  • . Subject's must be at least 18 kg/m2 but no more than 35 kg/m2.
  • Female subjects must have a negative serum pregnancy test at screening; as well as a negative urine pregnancy test prior to the PET scan on each day PET scans are performed, as well as prior to the MRI scan.

    1. Female subject of and male subject with female partner of childbearing potential must agree to use an acceptable form of from at least 30 days prior to administration of the first dose of study drug, during the treatment period, and 60 days after completion or premature discontinuation from the study drug. Male subjects must also refrain from semen/sperm donation 30 days prior to administration of the first dose of study drug, during the treatment period, and 60 days after completion or premature discontinuation from the study drug.

      • Adequate contraception is defined as continuous use of either two barrier methods (eg, condom and spermicide or diaphragm with spermicide) or a hormonal contraceptive. Acceptable hormonal contraceptives include the following: a) contraceptive implant (such as Norplant®) implanted at least 90 days prior to screening; b) injectable contraception (such as meroxyprogesterone acetate injection) given at least 14 days prior to screening; or c) oral contraception taken as directed for at least 30 days prior to screening. In the Investigator's judgment, the subject will adhere to this requirement.
    2. . Female subjects who are of non-childbearing potential are not required to abide by birth control requirements.

      • Non-childbearing potential is defined as subject who is surgically sterile, has undergone tubal ligation, or is (defined as at least 12 months of spontaneous amenorrhea or between 6 and 12 months of spontaneous amenorrhea with follicle stimulating hormone [FSH] concentrations within postmenopausal range as determined by laboratory analysis).
  • Subject is, in the opinion of the Investigator, generally healthy based on screening medical history, PE, neurological examination, vital signs, clinical laboratory values (hematology, serum chemistry urinalysis, lipid panel, coagulation panel, thyroid panel, and serum prolactin).
  • Subject has had a stable living arrangement at the time of screening and agrees to return to a similar living arrangement after discharge. This criterion is not meant to exclude subjects who have temporarily left a stable living arrangement (eg, due to psychosis). Such subjects remain eligible to participate in this study. Chronically homeless subjects should not be enrolled.
  • Subject must agree to comply with all medication restrictions for the required length of time.

Exclusion criteria

Exclusion criteria:

    1. Subject answers "yes" to "Suicidal Ideation" Items 4 (active suicidal ideation with some intent to act, without specific plan) or Item 5 (active suicidal ideation with specific plan and intent) on the C-SSRS at or during the Screening period (ie, in the past one month) and/or Day 1 (ie, since last visit).

      1. Subject does not tolerate venipuncture or has poor venous access that would cause difficulty for administration of the radioisotope and for collecting blood samples.
      1. Subject is currently participating in, or has participated in, a study with an or marketed compound or device within 3 months prior to signing the , or has participated in more than 2 studies of investigational compounds within 24 months prior to signing the informed consent.
      1. Subject has participated in a research and/or PET or radiological investigations with radiation exposure that, when combined with the dose from the present study, would exceed 10 mSv in addition to natural background radiation, in the previous 12 months.
      1. Subject has previously received SEP-363856.
      1. Subject has any unstable medical condition or any clinically significant chronic disease that in the opinion of the Investigator, would limit the subject's ability to complete and/or participate in the study:
      2. Clinically significant hematological (including deep vein thrombosis) or bleeding disorder, renal, metabolic, endocrine, pulmonary, gastrointestinal, urological, cardiovascular, hepatic, neurologic, or allergic disease (except for untreated, asymptomatic, seasonal allergies at time of dosing).
      3. Subject has a history of within 5 years prior to the Screening visit, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer. Subject has a pituitary tumor of any duration.
      4. Disorder or history of a condition, or previous gastrointestinal surgery (eg, cholecystectomy, vagotomy, bowel resection) that may interfere with drug absorption, distribution, metabolism, excretion, gastrointestinal motility, or pH, or a history of clinically significant abnormality of the hepatic or renal system, or a history of malabsorption.
      5. Subject currently has or has had within the last 6 months a diagnosis of Alcohol or Substance Abuse Disorder ( criteria). The only exceptions include caffeine or nicotine.
      6. Subject has a clinically significant abnormal 12-lead that may jeopardize the subject's ability to complete the study as determined by the Investigator or a screening 12-lead ECG demonstrating any one of the following: heart rate > 100 beats per minute, QRS > 120 ms, corrected for heart rate using Fridericia's formula (QTcF) > 450 ms (males), QTcF > 470 ms (females), or PR > 220 ms.
      7. Subjects with known history of (HIV) seropositivity.
      8. Subject has a history of clinically significant hypotensive disorder, systolic blood pressure less than or equal to 80 mmHg or a diastolic blood pressure less than or equal to 40 mmHG at any measurement prior to dosing on Day 1, or any clinically significant symptoms associated with hypotension at any time during participation prior to dosing on day 1.

        1. Female subject who is pregnant or lactating.

        8 Subject has a presence or history of a medically diagnosed, clinically significant psychiatric disorder (including intellectual disability, major depressive disorder with psychosis, and bipolar disorder) other than schizophrenia (medically diagnosed schizoaffective disorder or schizophreniform disorder will be allowed).

        1. Subject tests positive for drugs of abuse at screening, however, a positive test for barbiturates, opiates, benzodiazepines or methadone may not result in exclusion of subjects if the Investigator determines that the positive test is as a result of prescription medicine(s). In the event a subject tests positive cannabinoids (tetrahydrocannabinol), the Investigator will evaluate the subject's ability to abstain from using this substance during the study. This information will be discussed with the Medical Monitor prior to study enrollment.
        1. Subject is at significant risk of harming him/herself or others according to the Investigator's judgment.
        1. Subject has attempted suicide within 6 months prior to screening.
        1. Subject is involuntarily hospitalized.
        1. Subject is judged in the opinion of the Investigator to be severely resistant to antipsychotic treatment defined as a failure to respond to 4 or more marketed antipsychotic agents, given at an adequate dose as per labeling and for an adequate duration (lifetime).
        1. Subject is receiving an antipsychotic medication at a dose above the maximum labeled dose (country-specific) dose at or during the 3 for less than 12 weeks prior to the PET scan at the screening visit
        1. Subject has received clozapine treatment within 120 days of planned PET scan at screening.
        1. Subject has received electroconvulsive therapy treatment within the 3 months prior to screening or is expected to require ECT during the study.
        1. Subject has a history of allergy or to more than 2 distinct chemical classes of drug (eg, sulfonylureas and penicillins) allergic reaction to any medication or has a known or suspected sensitivity to any substance that is contained in the study drug formulation or to carbidopa or entacapone.
        1. Subject has any clinically significant abnormal laboratory values as determined by the Investigator (hematology, serum chemistry, urinalysis, lipid panel, coagulation panel, thyroid panel, and serum prolactin). (Note: abnormal findings of questionable significance will be discussed with the Medical Monitor prior to including subject).
        1. Subject demonstrates evidence of acute hepatitis, clinically significant chronic hepatitis, or evidence of clinically significant impaired hepatic function through clinical and laboratory evaluation. Note: Subjects with serum (ALT) or aspartate transaminase (AST) ≥ 3 times the upper limit of the reference ranges provided by the laboratory require retesting. If on retesting, the laboratory value remains ≥ 3 times the upper limit, the subject will be excluded.

        Note: subjects with serum alanine transaminase (ALT) or aspartate transaminase (AST) greater than or equal to 3 times the uper limit of the reference ranges provided by the laboratory require retesting. If on retesting, the laboratory value remains greater than or equal to 3 times the upper limit, the subject will be excluded.

        1. Subject has greater than or equal to 1.5 x (ULN) with the exception that isolated bilirubin greater than 1.5 x ULN is acceptable if bilirubin is fractioned and direct bilirubin less than 35% at screening.
        1. Subject has a serum blood urea nitrogen (BUN) or serum creatinine (Cr) value ≥ 1.5 times the upper limit of normal for the reference range.
        1. Subject has experienced significant blood loss (≥ 473 mL), has donated blood within 60 days prior to first dose of study drug, has donated plasma within 72 hours prior to the first dose of study drug or intends to donate plasma or blood or undergo elective surgery during study participation or within 60 days after the last study visit.
        1. Subject consumes more than 300 mg of caffeine per day (5 cups of coffee or equivalent in caffeinated beverages).
        1. Subject has used disallowed prescription or disallowed nonprescription drugs, or dietary or herbal supplements as specified within the Concomitant Medications and Restrictions for at least 5 half-lives or 14 days prior to dosing, whichever is longer, or anticipates the need for any disallowed medication during their participation in this study (exception: female subjects who are taking oral, patch, or intrauterine device [IUD] hormonal , or progestin implant or injection).
        1. Subject is a staff member or the relative of a staff member.
        1. Subject is in the opinion of the Investigator, unsuitable in any other way to participate in this study.
        1. Subject has to undergoing MRI/fMRI examination including, but not limited to claustrophobia, metal foreign bodies or implanted devices incompatible with the MRI/fMRI exposure.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    SEP-363856

    SEP-363856 50mg, 75mg flexible dosing, dosed once daily

    Drug: SEP-363856

Interventions

  • SEP-363856 50mg, 75mg flexable dosing, dosed once daily capsule

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Dopamine Synthesis Capacity at Week 2 Using 18F-DOPA.

    Dopamine synthesis capacity was assessed using 18 F-DOPA PET(positron emission tomography) scans that were performed before (baseline) and after (Week 2 \[Day 14\]) administration of SEP-363856 adjunctive to an antipsychotic medication. A repeated measures ANOVA(analysis of variance) analysis was conducted. The dependent variable was Dopamine Synthesis Capacity (Ki Values). The independent variables were Time and Striatal Subregion. The covariance matrix was unstructured for each subject's Time and Striatal Subregion.

    Time frame: baseline and week 2

07

Results

Posted Nov 25, 2024

Participant flow

Participant flow — Overall Study
MilestoneSEP-363856
Started22
Completed20
Not completed2
Withdrew: Withdrawal by subject1
Withdrew: Subject was withdrawn due to safety reason1

Outcome measures

PrimaryChange From Baseline in Dopamine Synthesis Capacity at Week 2 Using 18F-DOPA.

Dopamine synthesis capacity was assessed using 18 F-DOPA PET(positron emission tomography) scans that were performed before (baseline) and after (Week 2 \[Day 14\]) administration of SEP-363856 adjunctive to an antipsychotic medication. A repeated measures ANOVA(analysis of variance) analysis was conducted. The dependent variable was Dopamine Synthesis Capacity (Ki Values). The independent variables were Time and Striatal Subregion. The covariance matrix was unstructured for each subject's Time and Striatal Subregion.

Time frame:
baseline and week 2
Reported as:
Mean · Kicer
Change From Baseline in Dopamine Synthesis Capacity at Week 2 Using 18F-DOPA.
KicerSEP-363856
Whole Striatal Dopamine Synthesis Capacity-0.0007 ± 0.00157
Limbic Striatal Dopamine Synthesis Capacity-0.0008 ± 0.00118
Associative Striatal Dopamine Synthesis Capacity-0.0006 ± 0.00158
Sensorimotor Striatal Dopamine Synthesis Capacity-0.0008 ± 0.00207
Statistical analysis
  • SEP-363856 · Repeated Measures ANOVA · p = 0.0072 (A p-value of p\<0.05 will be considered as significant.)

Adverse events

Collected over Up to 36 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SEP-3638560/22 (0%)0/22 (0%)19/22 (86.4%)
Most frequent other events
Most frequent other events
EventSEP-363856
SomnolenceNervous system disorders14/22
DizzinessNervous system disorders8/22
Dry mouthGastrointestinal disorders4/22
HeadacheNervous system disorders4/22
NauseaGastrointestinal disorders3/22
Vision blurredEye disorders2/22
FatigueGeneral disorders2/22
PresyncopeNervous system disorders2/22
InsomniaPsychiatric disorders2/22

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)SEP-363856
<=18 years0
Between 18 and 65 years22
>=65 years0
Age, Continuous
Age, Continuous(Years)SEP-363856
Mean32.5 ± 6.68
Sex: Female, Male
Sex: Female, Male(Participants)SEP-363856
Female6
Male16
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SEP-363856
Hispanic or Latino1
Not Hispanic or Latino21
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SEP-363856
American Indian or Alaska Native0
Asian2
Native Hawaiian or Other Pacific Islander0
Black or African American11
White8
More than one race0
Unknown or Not Reported1
08

Study locations

1 site
  • Research Site
    London, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing. Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/

Data sharing details ↗ · clinical-trials.otsuka.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2019 to primary completion in Jun 2023, 45 months.

Results were first posted in Nov 2024, 1 year 5 months after primary completion.

Of 108 industry-sponsored phase 1 interventional studies under Schizophrenia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 45 months is above that.

Counting every sponsor, half of 133 studies reached it within 12 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2019
First posted
Jul 31, 2019
StartActual
Aug 7, 2019
Primary completionActual
Jun 6, 2023
CompletionActual
Jun 6, 2023
Results first posted
Nov 25, 2024
Last update
Dec 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04038957
Responsible party
Sponsor
First posted
Jul 31, 2019
Start date
Aug 7, 2019
Primary completion
Jun 6, 2023
Completion
Jun 6, 2023
Results posted
Nov 25, 2024
Last update
Dec 27, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SEP-363856

Start the discussion